BR9509985A - Solução para irrigação e método para inibição de dor inflamação e esparmo - Google Patents

Solução para irrigação e método para inibição de dor inflamação e esparmo

Info

Publication number
BR9509985A
BR9509985A BR9509985A BR9509985A BR9509985A BR 9509985 A BR9509985 A BR 9509985A BR 9509985 A BR9509985 A BR 9509985A BR 9509985 A BR9509985 A BR 9509985A BR 9509985 A BR9509985 A BR 9509985A
Authority
BR
Brazil
Prior art keywords
sparse
irrigation
inflammation
solution
inhibiting pain
Prior art date
Application number
BR9509985A
Other languages
English (en)
Inventor
Gregory A Demopulos
Jeffrey M Herz
Pamela A Pierce
Original Assignee
Omeros Med Sys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Med Sys Inc filed Critical Omeros Med Sys Inc
Priority claimed from PCT/US1995/016028 external-priority patent/WO1996019233A2/en
Publication of BR9509985A publication Critical patent/BR9509985A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/734Fullerenes, i.e. graphene-based structures, such as nanohorns, nanococoons, nanoscrolls or fullerene-like structures, e.g. WS2 or MoS2 chalcogenide nanotubes, planar C3N4, etc.
    • Y10S977/735Carbon buckyball
    • Y10S977/737Carbon buckyball having a modified surface
    • Y10S977/738Modified with biological, organic, or hydrocarbon material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition
    • Y10S977/916Gene therapy
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/919Dental

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9509985A 1995-12-12 1995-12-12 Solução para irrigação e método para inibição de dor inflamação e esparmo BR9509985A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35377595A 1995-12-12 1995-12-12
PCT/US1995/016028 WO1996019233A2 (en) 1994-12-12 1995-12-12 Irrigation solution and method for inhibition of pain, inflammation and spasm

Publications (1)

Publication Number Publication Date
BR9509985A true BR9509985A (pt) 1998-11-03

Family

ID=23390520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509985A BR9509985A (pt) 1995-12-12 1995-12-12 Solução para irrigação e método para inibição de dor inflamação e esparmo

Country Status (5)

Country Link
US (8) US5820583A (pt)
JP (1) JPH10510540A (pt)
AU (1) AU4467396A (pt)
BR (1) BR9509985A (pt)
NO (1) NO321094B1 (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
WO2000023062A2 (en) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
WO2000023061A2 (en) * 1998-10-21 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6796966B2 (en) * 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
MXPA00000009A (es) 1998-06-22 2005-09-08 Autologous Wound Therapy Inc Solicitud para patente de utilidad para curativo de heridas mejorado enriquecido con plaquetas.
ATE266399T1 (de) * 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
NZ511962A (en) * 1998-12-16 2003-06-30 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist, it's preparation, pharmaceutical compositions and use in antagonising the effects of the seratonin receptor
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6210392B1 (en) * 1999-01-15 2001-04-03 Interventional Technologies, Inc. Method for treating a wall of a blood vessel
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
JP2002537245A (ja) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト 5−ht3レセプターアンタゴニストの使用
EP1056014A1 (en) * 1999-05-28 2000-11-29 Hewlett-Packard Company System for providing a trustworthy user interface
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DE60012751T2 (de) * 1999-08-10 2005-01-20 Glaxo Group Ltd., Greenford Verwendung von EP 4 Rezeptorliganden zur Behandlung von neuropathischem Schmerz
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7445619B2 (en) 2000-08-18 2008-11-04 Map Technologies Llc Devices for electrosurgery
US7771422B2 (en) 2002-06-06 2010-08-10 Nuortho Surgical, Inc. Methods and devices for electrosurgery
US6902564B2 (en) * 2001-08-15 2005-06-07 Roy E. Morgan Methods and devices for electrosurgery
US7819861B2 (en) * 2001-05-26 2010-10-26 Nuortho Surgical, Inc. Methods for electrosurgical electrolysis
ITMO20010002A1 (it) * 2001-01-04 2002-07-04 Beniamino Palmieri Preparato per lavande e-o irrigazioni di cavita' naturali o patologiche del corpo umano
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
US7066932B1 (en) 2001-05-26 2006-06-27 Map Technologies Llc Biologically enhanced irrigants
US8591508B2 (en) * 2001-08-15 2013-11-26 Nuortho Surgical, Inc. Electrosurgical plenum
US8734441B2 (en) 2001-08-15 2014-05-27 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
US8235979B2 (en) 2001-08-15 2012-08-07 Nuortho Surgical, Inc. Interfacing media manipulation with non-ablation radiofrequency energy system and method
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1429710A1 (en) * 2001-08-27 2004-06-23 The Cleveland Clinic Foundation Compositions, methods and apparatus for surgical procedures
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
AU2003218045A1 (en) * 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
DK1941867T3 (da) * 2002-06-07 2012-01-02 Dyax Corp Polypeptid med modificeret Kunitz domæne
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
WO2004010894A2 (en) * 2002-07-30 2004-02-05 Omeros Corporation Ophthalmologic irrigation solutions and method
SI2386310T1 (sl) * 2002-08-28 2019-03-29 Dyax Corp. Metode za ohranjanje organov in tkiv
AU2002359404B2 (en) * 2002-11-12 2008-06-05 Omeros Corporation Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20050020690A1 (en) * 2002-12-18 2005-01-27 Algorx Infiltration of capsaicin into surgical sites and open wounds
EP1587506B1 (en) * 2002-12-18 2008-07-23 Algorx Administration of capsaicinoids
US20040147534A1 (en) * 2003-01-23 2004-07-29 Foote Mary Ann Topical composition and method for treating occlusive wounds
CA2423678A1 (en) * 2003-03-27 2004-09-27 Richard Bayly Method of inducing bleeding after dental surgery
NZ542887A (en) * 2003-04-08 2008-05-30 Algorx Pharmaceuticals Inc Preparation and purification of synthetic capsaicin
PL2374819T3 (pl) 2003-05-12 2017-09-29 Helion Biotech Aps Przeciwciała przeciwko MASP-2
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2005244036A1 (en) * 2004-05-14 2005-11-24 Universite De Laval Phospholipase C gamma modulation and uses thereof for management of pain and nociception
EP2457585A1 (en) 2004-06-10 2012-05-30 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060051338A1 (en) * 2004-08-20 2006-03-09 New York University Inhibition of mitogen-activated protein kinases in cardiovascular disease
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途
KR20130136010A (ko) 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Nos 저해 활성을 갖는 치환된 인돌 화합물
MX2007014496A (es) 2005-05-20 2008-02-11 Omeros Corp Composiciones de inhibidor de ciclooxigenasa y antagonista de los canales de calcio y metodos para usarlas en procedimientos urologicos.
WO2007025049A2 (en) * 2005-08-26 2007-03-01 Archemix Corp. Aptamers that bind thrombin with high affinity
US8328792B2 (en) 2005-10-27 2012-12-11 C. R. Bard, Inc. Enhanced pre-wetted intermittent catheter with lubricious coating
JP2009519962A (ja) * 2005-12-19 2009-05-21 コメンティス,インコーポレーテッド 眼投与用局所メカミルアミン製剤およびその使用
WO2007096782A2 (en) * 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
DE602007008545D1 (de) 2006-03-31 2010-09-30 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
EP2010527B1 (en) * 2006-04-13 2013-08-14 Neuraxon Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
AU2007247851A1 (en) * 2006-05-03 2007-11-15 Relevare Aust. Pty Ltd Methods and composition for treatment of inflammatory pain
EP2152074A4 (en) * 2007-04-30 2011-07-27 Adolor Corp (-) - E-10-OH-NT COMPOSITIONS, METHODS OF SYNTHESIS AND USE
WO2009046880A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
MX2010005343A (es) * 2007-11-16 2010-08-09 Neuraxon Inc Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
US20090163451A1 (en) * 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
WO2009062319A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
NZ603070A (en) * 2008-06-12 2013-08-30 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
US20100247671A1 (en) 2009-03-26 2010-09-30 Thomas Jeffrey E Method and composition for alleviating or preventing ischemic tissue damage
US9532827B2 (en) 2009-06-17 2017-01-03 Nuortho Surgical Inc. Connection of a bipolar electrosurgical hand piece to a monopolar output of an electrosurgical generator
WO2011014201A1 (en) 2009-07-29 2011-02-03 C. R. Bard, Inc. Catheter having improved drainage and/or a retractable sleeve and method of using the same
US9821139B2 (en) 2009-08-13 2017-11-21 C. R. Bard, Inc. Catheter having internal hydrating fluid storage and/or catheter package using the same and method of making and/or using the same
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
JP2013515572A (ja) 2009-12-23 2013-05-09 シー・アール・バード・インコーポレーテッド 水和/ヒドロゲルスリーブを用いたカテーテルアセンブリ/パッケージならびにその作製および使用方法
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US9033149B2 (en) 2010-03-04 2015-05-19 C. R. Bard, Inc. Catheter assembly/package utilizing a hydrating/hydrogel sleeve and a foil outer layer and method of making and using the same
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US9408658B2 (en) 2011-02-24 2016-08-09 Nuortho Surgical, Inc. System and method for a physiochemical scalpel to eliminate biologic tissue over-resection and induce tissue healing
RU2662563C2 (ru) 2011-04-08 2018-07-26 Юниверсити Оф Лестер Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
MX347691B (es) 2011-05-04 2017-05-09 Omeros Corp Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9579142B1 (en) 2012-12-13 2017-02-28 Nuortho Surgical Inc. Multi-function RF-probe with dual electrode positioning
EP3660011A1 (en) 2013-03-06 2020-06-03 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US8998882B2 (en) 2013-03-13 2015-04-07 C. R. Bard, Inc. Enhanced pre-wetted intermittent catheter with lubricious coating
HUE051746T2 (hu) 2013-10-17 2021-03-29 Omeros Corp Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére
IL295414A (en) 2014-03-27 2022-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema as a result of diabetes
ES2919874T3 (es) * 2014-09-24 2022-07-28 Vital Beverages Global Inc Composiciones y métodos para el suministro selectivo en el tubo gastrointestinal
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
EP3373963A4 (en) 2015-11-09 2019-07-10 Omeros Corporation METHODS OF TREATING SUFFERING RELATED TO MASP-2-DEPENDENT COMPLEMENTAL ACTIVATION
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3231452A1 (en) 2016-04-11 2017-10-18 DiCosmo, Frank Wound irrigation solutions
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
CN106512188A (zh) * 2016-12-13 2017-03-22 天津飞捷科技有限公司 机电一体化靶向药物释放介入类医疗器械及其制备方法
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
CN110123833A (zh) * 2019-05-31 2019-08-16 龚啸元 一种关节镜手术用灌流液及其制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971955A (en) * 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
US5616688A (en) * 1981-09-08 1997-04-01 The Rockefeller University Macrophage-derived inflammatory mediator (MIP-1α and MIP-1β)
US4443432A (en) * 1981-10-05 1984-04-17 Alcon Laboratories, Inc. Ophthmalic irrigating solution
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
DE3316510A1 (de) * 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
US4504493A (en) * 1983-07-15 1985-03-12 University Of Southern California By G. June Marshall Solution for surgical irrigation
US4659714A (en) 1984-03-27 1987-04-21 Dentsply, Ltd. Anesthetic methods for mammals
US4490379A (en) 1984-04-04 1984-12-25 Steven Podos Method of reducing intraocular pressure and treating glaucoma using corynanthine
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
US4872865A (en) * 1985-10-09 1989-10-10 Harrington Arthritis Research Center Hypertonic solution for arthroscopic surgery
FR2598081B1 (fr) * 1986-04-30 1990-02-02 Chauvin Blache Lab Procede de preparation d'une solution pharmaceutique aqueuse d'un principe actif constitue par un acide organique
JPS63115818A (ja) * 1986-08-27 1988-05-20 ジヨ−ジ・ア−ル・ケイリ−・ジュニア 術後痛の消滅又は改善のための局所用組成物
US5272139A (en) * 1986-08-27 1993-12-21 Cary George R Jr Amelioration or elimination of postoperative pain
US4938970A (en) * 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
JPH01135721A (ja) * 1987-10-29 1989-05-29 Geneco Inc 腹腔内感染を除去するための方法及び溶液
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE68927479T2 (de) 1988-05-02 1997-04-03 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
CA1341093C (en) * 1988-05-31 2000-09-05 Eugene P. Goldberg Method and composition for preventing surgical adhesions
USH1139H (en) * 1988-07-21 1993-02-02 E. R. Squibb & Sons, Inc. Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination
US5304724A (en) * 1988-09-09 1994-04-19 Entravision, Inc. Tissue irrigating solution
US5036046A (en) * 1988-10-12 1991-07-30 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5051443A (en) * 1988-10-12 1991-09-24 Eye Research Institute Of Retina Foundation, Inc. Method for enhancing healing of corneal endothelial wounds
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
GB8929076D0 (en) * 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation
DE69114470T2 (de) * 1990-09-07 1996-07-18 Univ Alicante Komposition für die behandlung von augenschmerzen.
ATE118168T1 (de) * 1990-12-03 1995-02-15 Vestar Inc Verhütung der synovialischen adhäsion.
US5536241A (en) 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
JP2520895Y2 (ja) * 1990-12-28 1996-12-18 曙ブレーキ工業株式会社 ディスクブレーキの圧油導入部
AU1579092A (en) 1991-02-27 1992-10-06 Nova Pharmaceutical Corporation Anti-infective and anti-inflammatory releasing systems for medical devices
WO1992018156A1 (en) * 1991-04-19 1992-10-29 Nova Technology Limited Partnership Bradykinin antagonist peptides
US5350761A (en) * 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
PT533280E (pt) 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
DE4135157C2 (de) * 1991-10-24 1995-06-14 Luitpold Pharma Gmbh Verwendung wäßriger Kohlenhydrat-Lösungen als Spülflüssigkeit für die Arthroskopie
US5502082A (en) * 1991-12-20 1996-03-26 Alliedsignal Inc. Low density materials having good compression strength and articles formed therefrom
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
ZA935078B (en) 1992-07-15 1994-02-07 Nicolaas Johannes Jaco Loetter Pharmaceutical composition
GB9216155D0 (en) * 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
DE69331387T2 (de) * 1992-09-10 2002-08-22 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5521158A (en) * 1992-10-08 1996-05-28 Scios Nova Inc. Pseudopeptide bradykinin receptor antagonists
US5288725A (en) 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
JPH07502544A (ja) * 1992-10-21 1995-03-16 アルコン ラボラトリーズ,インコーポレイテッド 眼内組織潅注用および眼内外科処置中の瞳孔散大維持用組成物
CA2158173C (en) * 1993-03-17 2001-12-04 Pietr Hitzig Method of treating addictive behaviors
DE4314976C1 (de) 1993-05-06 1994-10-06 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5417987A (en) * 1993-09-16 1995-05-23 Board Of Supervisors Of Louisiana State University Method for controlling bivalves such as zebra mussels
CA2179147A1 (en) * 1993-12-17 1995-06-22 Gerald D. Cagle Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent
WO1995019166A1 (en) 1994-01-14 1995-07-20 Shahinian Lee Jr A method for sustained and extended corneal analgesia
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5523316A (en) 1994-06-23 1996-06-04 Alcon Laboratories, Inc. Intraocular irrigating solution containing agent for controlling IOP
US5744482A (en) 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
US5480901A (en) 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5658955A (en) 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ,インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
MX9703988A (es) 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
WO1996029074A1 (en) * 1995-03-22 1996-09-26 Eli Lilly And Company Methods of treating or preventing pain or nociception
US5767105A (en) 1995-05-03 1998-06-16 Peyman; Gholam A. Ocular solution
WO1996041633A1 (en) 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1997024459A1 (en) 1995-12-29 1997-07-10 Phanos Technologoes, Inc. Method for reducing unwanted cellular adhesions
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5843016A (en) * 1996-03-18 1998-12-01 Physion S.R.L. Electromotive drug administration for treatment of acute urinary outflow obstruction
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Tnf媒介疾患を処置するためのtnf結合タンパク質を使用する組み合わせ治療
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain

Also Published As

Publication number Publication date
US6210394B1 (en) 2001-04-03
US5820583A (en) 1998-10-13
US6420432B2 (en) 2002-07-16
US6645168B2 (en) 2003-11-11
US6242447B1 (en) 2001-06-05
US20010044616A1 (en) 2001-11-22
US20030114355A1 (en) 2003-06-19
NO972687L (no) 1997-08-07
NO972687D0 (no) 1997-06-11
US6056715A (en) 2000-05-02
US6254585B1 (en) 2001-07-03
NO321094B1 (no) 2006-03-13
JPH10510540A (ja) 1998-10-13
AU4467396A (en) 1996-07-10
US6261279B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
BR9509985A (pt) Solução para irrigação e método para inibição de dor inflamação e esparmo
BR9708254A (pt) Método para o tratamento da dor
BR9710872A (pt) M-todo para crescimento e rendimento aumentados em plantas
NL194776B (nl) Plantenvermeerderingsinrichting en werkwijze.
BR9611024A (pt) Tratamento para rompimento de barreiras para pele estruturalmente deteriorada
BR9608742A (pt) Dispositivo contraceptivo e método e aparelho para montar mesmo
BR9705121A (pt) Método para fabricação de cateter
BR9603431A (pt) Método para tratar privação de abuso de substância
BR9608773A (pt) Tratamento bacteriano para silagem
PT788310E (pt) Metodo para inibir doencas nas plantas
FR2742679B1 (fr) Catalyseur d'hydrogenation selective et procede utilisant ce catalyseur
BR9609841B1 (pt) aparelho e mÉtodo para gerar raÍzes quadradas espectrais de linha de codificaÇço.
IT1281057B1 (it) Procedimento e dispositivo per la depurazione di acque.
BR9608746A (pt) Linhagem de célula produzindo compostos analgésicos para tratamento da dor
BR9708246A (pt) Metodo para tratamento de dor
ID19570A (id) Metode merawat tanaman kotiledonous
PT1089965E (pt) Derivados de ureia para tratamento da dor
FR2746261B1 (fr) Composition insecticide et procede de preparation
PT1051172E (pt) Metodo para tratamento da dpco
BR9709261A (pt) Método e aparelho para debulhamento de algodão
ES1031640Y (es) Dispositivo para el riego de plantas.
DE29517296U1 (de) Medikamententimer
ES1037988Y (es) Gotero para instalaciones de riego.
BR7502118U (pt) Disposição introduzida em aspersor para irrigação
UA25641A (uk) Осhова для лікарської форми, спосіб її отримаhhя та лікарська форма

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO, TENDO POR BASE O ARTIGO 8O COMBINADO COM O ARTIGO 13, E ARTIGO 25 DA LPI 9279 DE 14/05/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]